Cargando…

Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study

BACKGROUND: Docetaxel (DOC) plus ramucirumab (RAM) has been recommended as an optimal therapy for previously treated patients with non-small cell lung cancer (NSCLC). In a clinical setting, there are few reports about DOC plus RAM, therefore its effect on factors such as Eastern Cooperative Oncology...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsumoto, Kinnosuke, Tamiya, Akihiro, Matsuda, Yoshinobu, Taniguchi, Yoshihiko, Atagi, Shinji, Kawachi, Hayato, Tamiya, Motohiro, Tanizaki, Satoshi, Uchida, Junji, Ueno, Kiyonobu, Yanase, Takafumi, Suzuki, Hidekazu, Hirashima, Tomonori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107751/ https://www.ncbi.nlm.nih.gov/pubmed/34012781 http://dx.doi.org/10.21037/tlcr-20-1263

Ejemplares similares

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
por: Tamiya, Motohiro, et al.
Publicado: (2021)

Mediastinal undifferentiated pleomorphic sarcoma with pleural effusion cytopathologically misdiagnosed as epithelial malignant pleural mesothelioma: An autopsy case report
por: Matsumoto, Kinnosuke, et al.
Publicado: (2021)

Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer
por: Shiroyama, Takayuki, et al.
Publicado: (2017)

Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial
por: Tamiya, Motohiro, et al.
Publicado: (2018)

Treatment rationale and design of the RAMNITA study: A phase II study of the efficacy of docetaxel + ramucirumab for non–small cell lung cancer with brain metastasis
por: Tanimura, Keiko, et al.
Publicado: (2018)

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab
por: Hata, Akito, et al.
Publicado: (2018)

Efficacy of nanoparticle albumin-bound paclitaxel regimens for relapsed small cell lung cancer: A retrospective analysis
por: Naito, Yujiro, et al.
Publicado: (2017)

Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer
por: Nakao, Keiko, et al.
Publicado: (2019)

Poor effect of osimertinib on EGFR exon 20 insertion-positive lung adenocarcinoma: A case report
por: Inagaki, Yuji, et al.
Publicado: (2020)

Retrospective analysis of long‐term survival factors in patients with advanced non‐small cell lung cancer treated with nivolumab
por: Murakami, Yusuke, et al.
Publicado: (2022)

Important factors for achieving survival of five years or more in non-small cell lung cancer patients with distant metastasis
por: HIRASHIMA, TOMONORI, et al.
Publicado: (2014)

Dose reduction of docetaxel avoids the usage of pegfilgrastim in docetaxel plus ramucirumab therapy for recurrent nonsmall cell lung cancer
por: Hamai, Kosuke, et al.
Publicado: (2023)

Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study
por: Hosoya, Kazutaka, et al.
Publicado: (2021)

The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations
por: Suzuki, Hidekazu, et al.
Publicado: (2013)

Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma
por: Satoh, Shingo, et al.
Publicado: (2017)

Phase II study of ramucirumab and docetaxel for previously treated non‐small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study
por: Takemoto, Shinnosuke, et al.
Publicado: (2019)

Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
por: Shiono, Ayako, et al.
Publicado: (2019)

Interstitial lung disease induced by docetaxel and ramucirumab chemotherapy after nivolumab treatment
por: Okeya, Komugi, et al.
Publicado: (2020)

Right‐sided vocal cord paralysis following stereotactic body radiation therapy for non–small‐cell lung cancer: A case report
por: Kanaoka, Kensuke, et al.
Publicado: (2023)

Radial endobronchial ultrasound with a guide sheath for diagnosis of peripheral cavitary lung lesions: a retrospective study
por: Hayama, Manabu, et al.
Publicado: (2016)

Municipal Characteristics of In-Home Death Among Care-Dependent Older Japanese Adults
por: Abe, Kazuhiro, et al.
Publicado: (2022)

Cerebral infarction after treatment with dabrafenib plus trametinib for BRAF‐V600E‐positive non–small cell lung cancer: A case report
por: Taniguchi, Yoshihiko, et al.
Publicado: (2023)

Osteoblastic bone reaction in non-small cell lung cancer harboring epidermal growth factor receptor mutation treated with osimertinib
por: Kanaoka, Kensuke, et al.
Publicado: (2023)

Improvement of Mycobacterium abscessus Pulmonary Disease after Nivolumab Administration in a Patient with Advanced Non-small Cell Lung Cancer
por: Ishii, Seigo, et al.
Publicado: (2018)

Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan
por: Edahiro, Ryuya, et al.
Publicado: (2019)

Predictive factors for progression‐free survival in non‐small cell lung cancer patients receiving nivolumab based on performance status
por: Adachi, Yuichi, et al.
Publicado: (2019)

Enhancing tumour content and tumour cell count using microdissection contributes to higher detection rate of genetic mutations by next-generation sequencers()
por: Tamiya, Akihiro, et al.
Publicado: (2023)

Usefulness of High Suction Pressure for Sufficient Tissue Collection During Endobronchial Ultrasound Guided Transbronchial Needle Aspiration
por: Shiroyama, Takayuki, et al.
Publicado: (2013)

Mandatory dexamethasone strictly monitored by pharmacists reduces the severity of pemetrexed-induced skin rash
por: Usui, Naoko, et al.
Publicado: (2017)

The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non‐small cell lung cancer
por: Sakaguchi, Tadashi, et al.
Publicado: (2020)

Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment
por: Saito, Yoshitaka, et al.
Publicado: (2023)

Clinical significance of primary prophylactic pegylated‐granulocyte‐colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non‐small cell lung cancer
por: Mouri, Atsuto, et al.
Publicado: (2019)

A High PD-L1 Expression in Pulmonary Pleomorphic Carcinoma Correlates with Parietal-pleural Invasion and Might Predict a Poor Prognosis
por: Naito, Maiko, et al.
Publicado: (2018)

Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study
por: Kawachi, Hayato, et al.
Publicado: (2022)

Efficacy of subsequent docetaxel +/− ramucirumab and S‐1 after nivolumab for patients with advanced non‐small cell lung cancer
por: Tamura, Nobumasa, et al.
Publicado: (2019)

Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?
por: Nishimura, Tadashi, et al.
Publicado: (2022)

Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab
por: Morita, Mitsunori, et al.
Publicado: (2020)

Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group
por: Murakami, Haruyasu, et al.
Publicado: (2014)

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC
por: Imamura, Fumio, et al.
Publicado: (2020)

Comparison of the clinical courses and chemotherapy outcomes in metastatic colorectal cancer patients with and without active Mycobacterium tuberculosis or Mycobacterium kansasii infection: a retrospective study
por: Hirashima, Tomonori, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_g4khnd2j8f48dfrrp405ujc0ng